As the U.S. stock market kicks off February with a robust performance, highlighted by significant gains in major indices such as the Dow Jones Industrial Average and S&P 500, investors are closely watching the tech sector for potential high-growth opportunities. In this dynamic environment, identifying promising tech stocks involves considering factors like innovation, market demand, and adaptability to current economic conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Marker Therapeutics |
62.86% |
62.39% |
★★★★★★ |
|
Palantir Technologies |
26.32% |
28.56% |
★★★★★★ |
|
|
22.21% |
27.97% |
★★★★★★ |
|
Kiniksa Pharmaceuticals International |
15.03% |
30.82% |
★★★★★☆ |
|
Workday |
10.68% |
28.33% |
★★★★★☆ |
|
Sandisk |
29.12% |
45.57% |
★★★★★★ |
|
Procore Technologies |
12.08% |
101.39% |
★★★★★☆ |
|
Intapp |
12.01% |
100.87% |
★★★★★☆ |
|
Zscaler |
15.85% |
45.68% |
★★★★★☆ |
|
Duos Technologies Group |
53.76% |
155.11% |
★★★★★☆ |
Click here to see the full list of 72 stocks from our US High Growth Tech and AI Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for immune deficiencies and infectious diseases, with a market cap of approximately $3.80 billion.
Operations: The company’s revenue primarily comes from ADMA Biomanufacturing, contributing $481.64 million, with Plasma Collection Centers adding $6.77 million.
ADMA Biologics has demonstrated robust growth, with earnings surging by 207.4% over the past year, significantly outpacing the biotech industry’s average of 59.1%. This surge is supported by a strong pipeline and strategic market positioning, evidenced by their recent upward revisions in revenue projections for fiscal years 2025 through 2029, targeting over $1.1 billion in annual revenue by the latter year. Their commitment to R&D and innovation is evident from their presentations at significant industry conferences, like the J.P. Morgan Healthcare Conference, showcasing leadership in biotech advancements. With an expected annual profit growth rate of 21.6%, ADMA not only exceeds the U.S market average of 15.6% but also aligns with future revenue expectations set between $635 million to $775 million in the upcoming years.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: The Trade Desk, Inc. is a technology company that provides a global advertising platform, with a market capitalization of approximately $12.22 billion.
